Painful diabetic neuropathy was associated with lower quality of life and higher rates of depression and anxiety than painless diabetic neuropathy.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...

Some supplements may help manage neuropathic pain. Anti-inflammatory and antioxidant supplements may ... Benefits include: ...

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...

The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...

Neuropathic Pain Conditions - Covers diabetic neuropathy, postherpetic neuralgia (shingles-related pain), chemotherapy-induced peripheral neuropathy (CIPN), and complex regional pain syndrome ...

This advancement expands the Company's pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief.

Lexicon Pharmaceuticals, Inc. announced a conference call and webcast scheduled for March 3, 2025, at 8:00 a.m. ET to discuss topline results from the Phase 2b PROGRESS study of pilavapadin ...